Chris Cooley
Stock Analyst at Stephens & Co.
(3.09)
# 1,100
Out of 4,793 analysts
55
Total ratings
71.05%
Success rate
44.18%
Average return
Main Sectors:
Stocks Rated by Chris Cooley
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| VCEL Vericel | Maintains: Overweight | $39 → $42 | $41.92 | +0.19% | 2 | May 11, 2023 | |
| ALGN Align Technology | Maintains: Overweight | $500 → $375 | $153.51 | +144.28% | 7 | Jul 28, 2022 | |
| COO The Cooper Companies | Maintains: Overweight | $125 → $115 | $73.77 | +55.89% | 9 | Jun 3, 2022 | |
| ALC Alcon | Upgrades: Overweight | $86 → $92 | $83.82 | +9.76% | 4 | May 12, 2022 | |
| PLSE Pulse Biosciences | Maintains: Overweight | $14 → $12 | $15.08 | -20.42% | 2 | Apr 1, 2022 | |
| ANIK Anika Therapeutics | Downgrades: Equal-Weight | n/a | $14.01 | - | 2 | Mar 9, 2022 | |
| ESTA Establishment Labs Holdings | Maintains: Overweight | $88 → $90 | $32.30 | +178.64% | 3 | Nov 10, 2021 | |
| STE STERIS | Maintains: Overweight | $255 → $270 | $212.61 | +26.99% | 5 | Nov 4, 2021 | |
| GKOS Glaukos | Upgrades: Overweight | $60 → $68 | $83.65 | -18.71% | 5 | Nov 3, 2021 | |
| AVNS Avanos Medical | Downgrades: Equal-Weight | $60 → $45 | $13.42 | +235.32% | 2 | Aug 4, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $425 → $275 | $131.93 | +108.44% | 5 | Mar 23, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $56 → $37 | $15.92 | +132.41% | 2 | Mar 23, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $75 → $60 | $59.83 | +0.28% | 3 | Mar 23, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $48 → $35 | $89.70 | -60.98% | 2 | Mar 23, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $60 → $81 | $245.26 | -66.97% | 2 | Feb 22, 2018 |
Vericel
May 11, 2023
Maintains: Overweight
Price Target: $39 → $42
Current: $41.92
Upside: +0.19%
Align Technology
Jul 28, 2022
Maintains: Overweight
Price Target: $500 → $375
Current: $153.51
Upside: +144.28%
The Cooper Companies
Jun 3, 2022
Maintains: Overweight
Price Target: $125 → $115
Current: $73.77
Upside: +55.89%
Alcon
May 12, 2022
Upgrades: Overweight
Price Target: $86 → $92
Current: $83.82
Upside: +9.76%
Pulse Biosciences
Apr 1, 2022
Maintains: Overweight
Price Target: $14 → $12
Current: $15.08
Upside: -20.42%
Anika Therapeutics
Mar 9, 2022
Downgrades: Equal-Weight
Price Target: n/a
Current: $14.01
Upside: -
Establishment Labs Holdings
Nov 10, 2021
Maintains: Overweight
Price Target: $88 → $90
Current: $32.30
Upside: +178.64%
STERIS
Nov 4, 2021
Maintains: Overweight
Price Target: $255 → $270
Current: $212.61
Upside: +26.99%
Glaukos
Nov 3, 2021
Upgrades: Overweight
Price Target: $60 → $68
Current: $83.65
Upside: -18.71%
Avanos Medical
Aug 4, 2021
Downgrades: Equal-Weight
Price Target: $60 → $45
Current: $13.42
Upside: +235.32%
Mar 23, 2020
Maintains: Overweight
Price Target: $425 → $275
Current: $131.93
Upside: +108.44%
Mar 23, 2020
Maintains: Overweight
Price Target: $56 → $37
Current: $15.92
Upside: +132.41%
Mar 23, 2020
Maintains: Overweight
Price Target: $75 → $60
Current: $59.83
Upside: +0.28%
Mar 23, 2020
Maintains: Overweight
Price Target: $48 → $35
Current: $89.70
Upside: -60.98%
Feb 22, 2018
Maintains: Equal-Weight
Price Target: $60 → $81
Current: $245.26
Upside: -66.97%